| Patient | Flannery O'Connor |
|---|---|
| Date of birth | 1925-03-25 |
| Identifiers | MRN HR-ML046-SYN-TD; SSN (made up) 000-46-1853 |
| Document date | 1950-10-05 |
| Author | Augusta Pemberton-Diallo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; no new complaints. [S]
Ms. O'Connor returns for her yearly preventive visit, five months into treatment for lupus nephritis. Her joints and skin are quiet, and the three-month results showed the urine protein falling by half. She is on prednisone 7.5 mg a day, tapering. The bladder infection in June cleared with nitrofurantoin. She writes five mornings a week and has finished a draft of her novel. She completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 25 |
| Active conditions | Systemic lupus erythematosus with class III lupus nephritis on treatment |
| Medicines | Mycophenolate 1000 mg twice daily; belimumab 200 mg weekly; hydroxychloroquine 300 mg daily; losartan 25 mg daily; prednisone 7.5 mg daily, tapering; vitamin D3 1000 units daily |
| Recent events | Cystitis in June, resolved |
| Functional status | Independent; no morning stiffness |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and much better than in the spring |
| Psychosocial | Supported by friends and her writing community; feels safe; health insurance covers her medicines |
| Behavioral | Never smoker; alcohol rarely; walks most days; sunscreen and a hat outdoors |
| Activities of daily living | Independent in all |
| Instrumental activities of daily living | Manages her medicines, injections, money, and correspondence |
| Sexual and reproductive health | One long-term partner; intrauterine system in place; not planning pregnancy this year |
| Home safety | Smoke detectors working; wears a seat belt; gloves and a mask when cleaning the bird pens |
| Hearing and vision | Baseline eye examination for hydroxychloroquine in June normal; hearing normal |
| Sleep | Eight hours; less fatigue |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight stable after a small gain on prednisone |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No mouth ulcers |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or pleuritic pain |
| Gastrointestinal | Negative | No diarrhea or abdominal pain on mycophenolate |
| Genitourinary | Negative | No urinary symptoms; light periods with the intrauterine system |
| Musculoskeletal | Negative | No joint pain; no hip, groin, or knee pain |
| Integumentary | Negative | No rash; hair regrowing |
| Neurological | Negative | No headaches or seizures |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 1950-04-13 | active | S |
| Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term | One tablet once daily | Oral route | 1950-04-22 | active | S |
| Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure | One tablet once daily | Oral route | 1950-04-22 | active | S |
| Methylprednisolone 500 mg intravenous infusion once daily for three days | One infusion daily for three days | Intravenous route | 1950-04-29 to 1950-05-01 | completed | S |
| Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months | Once daily, tapering | Oral route | 1950-04-29 | active | S |
| Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily | Two tablets twice daily | Oral route | 1950-04-29 | active | S |
| Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly | Once weekly by self-injection | Subcutaneous route | 1950-04-29 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 1950-04-29 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days | One capsule twice daily for seven days | Oral route | 1950-06-15 to 1950-06-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1950-10-05 | Body height | 168 | cm | S |
| 1950-10-05 | Body weight | 62.2 | kg | S |
| 1950-10-05 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 1950-10-05 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1950-10-05 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1950-10-05 | Heart rate | 70 | /min | S |
| 1950-10-05 | Respiratory rate | 14 | /min | S |
| 1950-10-05 | Body temperature | 36.6 | Cel | S |
| 1950-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1950-10-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1950-10-05 | Total score [AUDIT-C] | 1 | {score} | S |
Vital signs recorded on 1950-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well-appearing; BMI 22.0 |
| Eyes | Pupils equal and reactive |
| Mouth | No ulcers; teeth in good repair |
| Neck | No nodes |
| Cardiovascular | Regular rhythm; no murmur or rub; no edema |
| Respiratory | Clear |
| Musculoskeletal | No synovitis; full, painless hip movement |
| Skin | No malar or discoid rash; no suspicious moles |
| Psychiatric | Engaged and funny |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established | resolved | confirmed | M25.50 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D). |
| Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established | resolved | confirmed | R80.9 | S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit. |
| Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative | active | confirmed | M32.19 | S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used. |
| Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function | active | confirmed | M32.14 | S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used. |
| Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less | active | confirmed | Z79.52 | S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low. |
| Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place | active | confirmed | Z79.624 | S — Synthetic treatment status. |
| Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment | active | confirmed | Z97.5 | S — Synthetic contraception, chosen by the patient. |
| Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoin | resolved | confirmed | N30.00 | S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 1950-1951 | Completed today | Inactivated vaccine given today; live vaccines are avoided on immunosuppression |
| COVID-19 vaccine, 1950-1951 | Due | Recommended; booked at her pharmacy next week |
| Pneumococcal vaccine | Up to date | PCV20 in April, recommended for immunocompromised adults; no further doses |
| Recombinant zoster vaccine | Up to date | Two doses, in April and July, recommended from 19 for immunocompromised adults |
| HPV vaccine | Up to date | Series completed in adolescence |
| Hepatitis B vaccine | Up to date | Vaccinated in infancy; surface antibody positive and surface antigen negative in April |
| Tetanus booster | Up to date | Tdap seven years ago |
| Cervical cancer screening | Ordered | Cytology with HPV testing today, yearly while immunosuppressed |
| Hepatitis C and HIV screening | Up to date | Negative in April, before immunosuppression |
| Chlamydia and gonorrhea screening | Not indicated | Age 25 with one long-term partner; offered if risk changes |
| Contraception | Up to date | Levonorgestrel intrauterine system since April; required while on mycophenolate |
| Folic acid | Completed today | Advised 0.4 mg daily, as for all who could become pregnant |
| Blood pressure screening | Completed today | 116/74 mmHg on losartan |
| Cholesterol and diabetes | Up to date | LDL 128 mg/dL and HbA1c 5.3 percent in July on prednisone; no statin; recheck at one year on a low dose |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 1, negative |
| Skin cancer prevention and sun protection | Completed today | Daily broad-spectrum sunscreen and a hat, also for lupus photosensitivity |
| Physical activity and diet counseling | Completed today | Walking most days; calcium-rich foods; low salt for blood pressure and the kidneys |
Immunizations given today: Influenza vaccine, 1950-1951 season [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Cervical screening result by portal message. Six-month lupus nephritis assessment this month. COVID-19 vaccine next week. Next scheduled visit 1950-10-26: six-month response assessment: complete renal response; prednisone 5 mg; pregnancy planning. [S]
Voluntary advance care planning discussion of about 15 minutes, with her consent. She has named a close friend as her health care agent and completed a written health care directive today, now scanned into the chart. Her first instruction is that she is to be told the truth about her illness directly, and that no clinician is to give her information to anyone else before giving it to her. She would want full treatment for a lupus flare or an infection; she would not want prolonged life support if she could not expect to recover the ability to read and write. [S]